PMI's IQOS Revenue Surpasses Marlboro, Aiming for 100B sales

Oct.11.2024
PMI's IQOS Revenue Surpasses Marlboro, Aiming for 100B sales
According to El Economista on October 9, Philip Morris International's IQOS device surpasses Marlboro in revenue, reaching $10 billion.

According to El Economista on October 9th, 38% of Philip Morris International's (PMI) global net income comes from non-cigarette alternative products. Revenue from their heated tobacco device "IQOS" has surpassed that of their most important cigarette brand Marlboro for the first time, with IQOS projected to exceed $10 billion in global sales by 2023.


It is reported that PMI's cigarette alternative products have now entered over 90 markets worldwide, with a total investment of $14 billion and a team of 1,500 people working on innovation.


The company's CEO, Jacek Olczak, stated during a media briefing in Neuchâtel, Switzerland, that...


The figures we have achieved are remarkable. Despite realizing that the market is developing faster than expected, there is still a long way to go.


Eujia further emphasized that it took IQOS 10 years to achieve sales of $10 billion, while Meta took 9 years, Amazon took 12 years, and Tesla took 14 years.


Philip Morris International (PMI) believes that there are 1.1 billion smokers worldwide and that the current measures being implemented are not effective enough. The IQOS device was initially launched in Milan, Italy, and Nagoya, Japan, and now has 30.8 million users. Oscar Jager stated, "In some countries, such as Japan, alternatives have already surpassed traditional cigarettes." He further emphasized that the company will continue to invest in new innovations to accelerate the transformation and aims to achieve 66% of revenue from alternatives by 2030.


However, the spokesperson acknowledged that due to insufficient information, many countries are skeptical of alternative products.


Some activists claim that these products are just as harmful as cigarettes, but we have proven that this is not true. People need to make informed decisions, as there is no scientific research indicating that these products are exactly the same as cigarettes.


Ouyaje criticized some government's strict regulation.


They refuse to listen to our advice because we are a tobacco company, but all of this is based on scientific data - nicotine does not cause cancer. This situation is similar to the COVID-19 vaccine, where some people are unwilling to get vaccinated despite scientific evidence.


He also stated that the World Health Organization "even refused to respond to our information".


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Supreme Vape Revenue Rises 15% Despite UK Disposable Vape Ban
Supreme Vape Revenue Rises 15% Despite UK Disposable Vape Ban
UK consumer goods group Supreme said its vaping revenue rose 15% to £148.1 million in the year to March 31, 2026, despite the UK disposable vape ban taking effect during the period, while the company identified the Vaping Products Duty due in October as the next major industry milestone.
Regulations
Jul.03 by 2Firsts Perspectives
Illegal Vape Sellers Still Use TikTok and Other Platforms to Drive Sales Despite Australia’s Ad Ban
Illegal Vape Sellers Still Use TikTok and Other Platforms to Drive Sales Despite Australia’s Ad Ban
Illegal vape sellers are still promoting nicotine products on TikTok, Instagram and YouTube despite Australia’s 2024 advertising ban, while illicit tobacco sales are increasingly moving from physical stores to online marketplaces.
Jul.15
Chinese Disposable Brands OXBAR, LYCO Challenge Vuse and JUUL: Pennsylvania’s Pending List Offers a Glimpse of the Future Legal Vape Market
Chinese Disposable Brands OXBAR, LYCO Challenge Vuse and JUUL: Pennsylvania’s Pending List Offers a Glimpse of the Future Legal Vape Market
Pennsylvania’s June 26 ENDS Pending Certifications list previews the state’s future legal vape market, placing Vuse, JUUL and Logic alongside Chinese-linked disposable brands OXBAR and LYCO. Shaped by PMTA eligibility and state rules, the list shows competition shifting from market share to market access.
Special Report
Jul.06
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
A new Swedish study found oral mucosal lesions in 79% of examined nicotine pouch users and 89% of tobacco-derived snus users, with different tissue-response patterns between the two categories. For manufacturers and regulators, the findings shift attention toward product formulation, flavouring, pouch materials and local oral exposure, not only whether a product contains tobacco. The study found no higher prevalence of caries or periodontal disease, but it could not establish causality, long-term outcomes or differences between individual products or designs.
Special Report
Jul.27
Reuters: Shopify May Ban All Vape Sales This Week Amid Illegal Market Crackdown
Reuters: Shopify May Ban All Vape Sales This Week Amid Illegal Market Crackdown
Reuters reported that Shopify may ban all vape products from its platform as soon as this week, signaling that U.S. enforcement against the illegal vape market is expanding from retailers and importers to e-commerce platforms and payment networks.
MarketBAT
Jun.23 by 2Firsts Perspectives
Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland’s Public Health (Tobacco Products and Nicotine Inhaling Products) (Amendment) Bill 2026 has passed final stage in the Dáil and will move to the Seanad, with measures to limit vape flavours to tobacco or unflavoured products and tighten rules on packaging colours, retail advertising, in-store displays and sales of nicotine pouches to minors.
News
Jun.26 by 2Firsts Perspectives